Your Health, We Care
Alpelisib is the world's first approved PI3K inhibitor for the treatment of solid tumors, developed by Novartis.
There are multiple clinical studies underway internationally on Alpelisib, aimed at further exploring its efficacy and safety in different diseases. These studies include but are not limited to PROS and breast cancer.
Alpelisib is a drug for the treatment of HR/HER2- breast cancer, especially for ···【more】
Release date：2024-08-22Recommended：211
Alpelisib for the treatment of PIK3CA-mutated HR/HER2- advanced breast cancer in···【more】
Release date：2024-08-22Recommended：207
Alpelisib, approved in combination with fulvestrant in 2019 for the treatment of···【more】
Release date：2024-08-22Recommended：224
